All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2018-09-13T10:19:41.000Z

Orphan Drug Designation granted for quizartinib in Japan for the treatment of FLT3-mutated acute myeloid leukemia

Sep 13, 2018
Share:

Bookmark this article

On 11 September 2018, Japan’s Ministry of Health, Labor, and Welfare (MHLW)  granted Orphan Drug Designation to quizartinib, an oral, highly potent and selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, for the treatment of adult patients with FLT3-mutated acute myeloid leukemia (AML). This comes after Breakthrough Therapy Designation was granted to quizartinib by the  U.S. Food and Drug Administration (FDA) last month.

The pivotal phase III randomized QuANTUM-R study is assessing the efficacy and safety of quizartinib (60-mg, with a 30-mg lead-in for 15 days) versus salvage chemotherapy (SC) in patients with R/R FLT3-ITD-mutated AML. Data from this study showed that quizartinib significantly prolonged overall survival in patients with R/R FLT3-ITD AML compared to SC. More results from this phase III randomized study are reported here.

Jorge Cortes, in an interview with the AML Global Portal (AGP), highlighted that the QuANTUM-R trial was a “very positive study”, and he hopes that it leads to a “regulatory approval” for quizartinib as it “offers an advantage” over the current treatment options for these difficult to treat patients.

  1. PR Newswire: Daiichi Sankyo's FLT3 Inhibitor Quizartinib Receives Orphan Drug Designation from Japanese MHLW for FLT3-Mutated AML. 2018 Sep 11. https://www.prnewswire.com/news-releases/daiichi-sankyos-flt3-inhibitor-quizartinib-receives-orphan-drug-designation-from-japanese-mhlw-for-flt3-mutated-aml-300709801.html [Accessed 2018 Sep 12].

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 77 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox